ScreenerHero

CVKD Cadrenal Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cadrenal.com
0.9723USD-1.79%Mkt Cap: 3.01M $P/E: —

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.01M USD
Enterprise Value1.14M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.24M USD
Revenue/Share—
Last Price0.9723 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.29
PEG—
EV/EBITDA-0.10
EV/Revenue—
P/S—
P/B0.75
EPS (TTM)-4.91
EPS (Forward)-3.40
52W Range
0.86011% of range14.64
52W High14.64 USD
52W Low0.8601 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-483.34%
ROA-305.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.60M USD
CapEx (TTM)5.10K USD
FCF Margin—
FCF Yield-283.38%
Net Debt-2.39M USD
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity—
Current Ratio3.73
Quick Ratio3.39
Book Value/Sh1.32 USD
Cash/Share0.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 20, 2024
Analyst Consensus
Rating—
Target (Mean)14.00 USD
Upside (mean)+1339.9%
Target Range12.00 USD – 17.00 USD
12.00+1339.9% to mean17.00
# Analysts3
Ownership
Shares Out.3.10M
Float3.22M
Insiders9.66%
Institutions9.75%
Short Interest
Short Ratio0.1d
Short % Float3.72%
Short % Out.3.33%
Shares Short118.80K
Short (prev mo.)65.08K
Technical
SMA 501.492 (-34.8%)
SMA 2004.566 (-78.7%)
Beta1.95
S&P 52W Chg16.45%
Avg Vol (30d)186.29K
Avg Vol (10d)114.35K
Technical Indicators
RSI (14)29.7
MACD-0.1744
MACD Signal-0.1953
MACD Hist.+0.0209
BB Upper1.289 USD
BB Middle1.091 USD
BB Lower0.8940 USD
BB Width36.17%
ATR (14)0.1290 USD
Vol Ratio (20d)15.44x